JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the sec ...

Core Insights - REGENXBIO Inc. will host a conference call on November 6, 2025, at 8:00 a.m. ET to discuss its Q3 financial results and operational highlights [1][2]. Company Overview - REGENXBIO is a biotechnology company focused on gene therapy, founded in 2009, and has pioneered AAV gene therapy [3]. - The company is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne, clemidsogene lanparvovec (RGX-121) for MPS II, and RGX-111 for MPS I, in partnership with Nippon Shinyaku [3]. - REGENXBIO is also collaborating with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [3]. - Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [3]. - The investigational gene therapies have the potential to significantly impact healthcare delivery for millions [3].

NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the third quarter of 2025 and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcas ...

Core Insights - Seres Therapeutics has received up to $3.6 million in non-dilutive funding from CARB-X to support the development of an oral liquid formulation of SER-155, aimed at improving access for medically vulnerable patients, particularly those in intensive care who cannot take oral capsules [1][3][5] - SER-155 is being developed for patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) and has shown a 77% reduction in bacterial bloodstream infections (BSIs) compared to placebo in a Phase 1b study [2][5] - The development of a liquid formulation is expected to broaden the impact of SER-155 in additional high-risk patient populations susceptible to BSIs and antimicrobial resistant infections [3][5] Funding and Support - CARB-X, a global non-profit partnership, is providing funding to accelerate the development of antibacterial products, specifically targeting drug-resistant bacteria [1][4] - The funding is supported by various federal and international health organizations, including the U.S. Department of Health and Human Services and the UK Department of Health and Social Care [3][4] Clinical Development - SER-155 has received Breakthrough Therapy designation and Fast Track designation from the FDA, indicating its potential to significantly reduce the risk of infections in allo-HSCT patients [5][6] - The company is finalizing the clinical protocol for a well-powered, placebo-controlled Phase 2 study following positive feedback from the FDA [2][5] Company Background - Seres Therapeutics is focused on improving outcomes for medically vulnerable populations through live biotherapeutics and has previously developed VOWST™, the first FDA-approved orally administered microbiome therapeutic [5][6] - The company aims to evaluate SER-155 in various patient populations, including those undergoing autologous-HSCT, cancer patients with neutropenia, and patients in intensive care [6]

Core Insights - NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of the ITOL-102 cell therapy program for Type 1 Diabetes under the merged entity NewCelX Ltd. following their merger [1][3][4] Group 1: Company Overview - NLS Pharmaceutics is a biopharmaceutical company focused on innovative therapies for central nervous system disorders [5] - Kadimastem is a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes [6] Group 2: ITOL-102 Program - The ITOL-102 program aims to develop a functional, stem-cell-derived pancreatic islet cell therapy to cure Type 1 Diabetes without lifelong immunosuppression [3] - The BIRD Foundation, which has invested over $300 million in joint projects since 1977, will continue to support the ITOL-102 program under NewCelX [2][4] Group 3: Strategic Focus - The merger allows NLS to leverage Kadimastem's advanced stem-cell platform, expanding its pipeline into regenerative and metabolic medicine [4]

Core Viewpoint - Tango Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 4, 2025, at 9:00 am ET, prior to the opening of U.S. financial markets, and will not hold a conference call [1] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2] - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2]

Oct 29, 2025 6:30 AM Eastern Daylight Time Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors Share LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a par ...

Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [1] - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [1] - The company is participating in several industry and investor conferences in November, including BIO-Europe and the Jefferies Global Healthcare Conference [3] Company Overview - Immunic, Inc. is listed on Nasdaq under the ticker IMUX and specializes in therapies for chronic inflammatory and autoimmune diseases [1] - Vidofludimus calcium acts as a first-in-class nuclear receptor-related 1 (Nurr1) activator and selectively inhibits dihydroorotate dehydrogenase (DHODH) [1] - Other development programs include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [1] Clinical Development - Vidofludimus calcium has shown therapeutic activity in phase 2 trials for relapsing-remitting and progressive multiple sclerosis [1] - IMU-856 aims to restore intestinal barrier function and could be applicable in various gastrointestinal diseases [1] - IMU-381 is being developed to address specific needs in gastrointestinal diseases and is currently in preclinical testing [1]

Core Points - NLS Pharmaceutics Ltd. plans to execute a reverse share split at a ratio of 1-for-10, effective on October 30, 2025, in conjunction with a merger with Kadimastem Ltd. [1][2] - Following the reverse split, the company's common shares will trade under the new symbol "NCEL" starting October 31, 2025 [1][2] - The reverse split will also apply to preferred shares and preferred participation certificates at the same 1-for-10 ratio [3] Company Structure Post-Merger - After the reverse split and merger, the company's registered capital will consist of CHF 282,908.80, divided into 5,533,183 common shares and 124,993 preferred shares, among other capital structures [4] - The total outstanding common shares will be 4,558,378, with additional shares issuable upon the exercise of pre-funded warrants [6] Shareholder Impact - No fractional shares will be issued; instead, cash will be provided for any fractional shares resulting from the reverse split [5] - The reverse split will not affect shareholders' percentage ownership or voting power, aside from minor adjustments due to fractional shares [5]

Core Insights - In September, the OTC market in the U.S. welcomed 30 new companies, a decrease of 9 compared to the previous month [1] - There were 5 companies that transitioned from OTC to the main board, an increase of 3 from August [1] - The new listings came from 6 countries, with Canada accounting for 47% of the new companies [1] - As of September 30, 2025, there are 12,278 companies listed on the U.S. OTC market, with a transaction volume of $61.2 billion for the month and $527.1 billion year-to-date [1] New Listings - The following companies were newly listed in September: - EMPIRE METALS LTD (OTCQX: EPMLF) - VERUSA HOLDING A S (OTCQX: VRSHF) - ACG Metals Limited (OTCQX: ACGAF) - FIRST NORDIC METALS CORP. (OTCQX: FNMCF) - Bitcoin Treasury Corporation (OTCQX: BTCFF) - Radisson Mining Resources Inc. (OTCQX: RMRDF) - Bonvenu Bancorp, Inc. (OTCQX: BBNA) - Associated Capital Group, Inc. (OTCQX: ACGP) - Horizon Kinetics Holding Corporation (OTCQX: HKHC) - Capstone Green Energy Holdings Inc. (OTCQX: CGEH) - Pacifica Silver Corp. (OTCQB: PAGFF) - BIONXT SOLUTIONS INC. (OTCQB: BNXTF) - Metalsource Mining Inc. (OTCQB: SFRIF) - Orogen Royalties Inc (OTCQB: OGNNF) - SUPERQ QUANTUM COMPUTING INC (OTCQB: QBTQF) - WESTERN STAR RES INC. (OTCQB: WSRIF) - Top End Energy Limited (OTCQB: SERPY, TNDEF) - Hamak Gold Limited (OTCQB: HASTF) - IMA TECH (OTCQB: IMAA) - TOKENWELL PLATFORMS INC. (OTCQB: TWELF) - Crypto Blockchain Industries, SA (OTCQB: CBIPF) - GREENLAND RES INC. (OTCQB: GRLRF) - Nexcel Metals Corp. (OTCQB: NXXCF) - Atex Resources Inc. (OTCQB: ATXRF) - Longevity Health Holdings, Inc. (OTCQB: XAGE) - PRINCE SILVER CORP (OTCQB: PRNCF) - Grayscale Near Trust (OTCQB: GSNR) - ConnectM Technology Solutions, Inc. (OTCQB: CNTM) - Eco Bright Future, Inc. (OTCQB: EBFI) - dMY Squared Technology Group, Inc. (OTCQB: DMYY, DMYYW) [1] Companies Transitioning to Main Board - Sono Group N.V. transitioned to NASDAQ with the ticker SSM on September 5, 2025, focusing on solar technology development and applications [2] - Sol Strategies, Inc. transitioned to NASDAQ with the ticker STKE on September 9, 2025, specializing in Solana blockchain infrastructure [3] - Spruce Biosciences, Inc. transitioned to NASDAQ with the ticker SPRB on September 15, 2025, focusing on innovative therapies for rare endocrine diseases [7] - Grayscale transitioned to NYSE MKT with the ticker GDLC on September 19, 2025, as a multi-asset cryptocurrency fund [8] - BTQ Technologies Corp. transitioned to NASDAQ with the ticker BTQ on September 26, 2025, focusing on quantum computing and cybersecurity [8]